IGF1R (Ab-1165/1166) Antibody

What is IGF1R (Ab-1165/1166) Antibody and what epitope does it target?

IGF1R (Ab-1165/1166) Antibody is a polyclonal antibody that specifically recognizes the insulin-like growth factor-I receptor (IGF1R) at the Ab-1165/1166 region. This antibody is generated using a synthetic peptide of human IGF1R corresponding to the 1165/1166 amino acid residues as the immunogen. It is primarily designed for research applications requiring specific detection of IGF1R in various experimental systems .

The epitope targeted by this antibody is significant because it corresponds to a region involved in the receptor's phosphorylation and activation mechanisms, making it valuable for studying IGF1R signaling dynamics in different cellular contexts.

What is the biological significance of IGF1R in research contexts?

IGF1R is a receptor tyrosine kinase (RTK) that plays critical roles in multiple cellular processes including:

• Cell cycle progression and proliferation

• Prevention of apoptosis (programmed cell death)

• Mediation of growth hormone responses

• Cell metabolism regulation

• Tissue differentiation and development

From a research perspective, IGF1R is significant because it influences both normal physiological processes and pathological conditions. It functions as a transmembrane molecular scaffold that, upon ligand binding, activates downstream signaling pathways including PI3K/AKT, MAPK/ERK, and JAK/STAT, which collectively regulate cellular growth, survival, and metabolism .

In developmental biology, IGF1R plays crucial roles in embryonic development, bone growth, and neuroprotection. In pathological contexts, aberrant activation of IGF1R signaling has been implicated in various cancers, including breast, lung, and colorectal malignancies, making it an important target for oncology research .

What are the molecular characteristics and synonyms of IGF1R?

The IGF1R protein has several important molecular characteristics relevant to research applications:

The protein belongs to the insulin receptor family and is expressed in a wide variety of tissues and cell types. Understanding these molecular details is critical for experimental design, especially when conducting research involving protein expression, purification, or analysis .

What validated applications exist for IGF1R (Ab-1165/1166) Antibody?

The IGF1R (Ab-1165/1166) Antibody has been validated for several research applications:

• Western Blotting (WB): The primary validated application, useful for detecting IGF1R protein expression levels in cell or tissue lysates .

• Flow Cytometry: Can be used to analyze IGF1R expression on cell surfaces, as demonstrated in protocols using HeLa cells with appropriate secondary antibodies such as FITC-conjugated goat anti-mouse/rabbit IgG .

• Immunohistochemistry: While not explicitly mentioned in all sources, polyclonal antibodies against IGF1R are commonly used for tissue staining.

• ImmunoPET Imaging: Specialized application for in vivo visualization of IGF1R expression, particularly in cancer models such as prostate cancer xenografts .

Each application requires specific optimization for reliable results, including antibody dilution, incubation conditions, and detection methods.

What is the optimal protocol for Western Blotting with IGF1R (Ab-1165/1166) Antibody?

For optimal Western Blotting results with IGF1R (Ab-1165/1166) Antibody, researchers should follow this methodological approach:

• Sample Preparation:

  • Lyse cells or tissues in a buffer containing protease and phosphatase inhibitors

  • Determine protein concentration using Bradford or BCA assay

  • Prepare 20-50 μg of protein per lane with reducing sample buffer

• Gel Electrophoresis:

  • Use a discontinuous SDS-PAGE system with 5% enrichment gel and 10-15% separation gel

  • Include molecular weight markers with range covering ~154.8 kDa

• Transfer:

  • Transfer proteins to PVDF or nitrocellulose membrane

  • Confirm transfer efficiency with reversible staining (Ponceau S)

• Blocking:

  • Block membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary Antibody Incubation:

  • Dilute IGF1R (Ab-1165/1166) Antibody (optimal dilution should be determined empirically, typically 1:500-1:2000)

  • Incubate overnight at 4°C with gentle rocking

• Washing and Secondary Antibody:

  • Wash membrane 3x with TBST

  • Incubate with HRP-conjugated anti-rabbit secondary antibody (typically 1:5000) for 1 hour

  • Wash 3x with TBST

• Detection:

  • Apply ECL substrate and image using appropriate detection system

  • Expected band size is approximately 95 kDa (β-subunit) and/or 200 kDa (full receptor)

The antibody comes in PBS with 0.05% sodium azide and 50% glycerol (pH 7.3), which should be considered when calculating final buffer compositions for your experiment .

How can IGF1R (Ab-1165/1166) Antibody be effectively used in flow cytometry?

For effective flow cytometry applications with IGF1R (Ab-1165/1166) Antibody, researchers should implement the following protocol:

• Cell Preparation:

  • Harvest cells of interest (e.g., HeLa cells for positive control)

  • Adjust concentration to approximately 1×10^6 cells/mL

  • Wash cells in cold PBS containing 1-2% serum or BSA

• Antibody Incubation:

  • Incubate cells with IGF1R (Ab-1165/1166) Antibody at an optimized concentration (approximately 0.5-1 μg/mL) for 30 minutes at room temperature

  • For negative controls, use isotype control antibody (mouse IgG1) at equivalent concentration

• Washing:

  • Wash cells three times with cold PBS to remove unbound antibody

• Secondary Antibody:

  • Incubate with fluorophore-conjugated secondary antibody (e.g., FITC-labeled rabbit anti-mouse/rabbit IgG at 1 μg/mL) for 30 minutes at room temperature

  • Alternatively, if using a directly conjugated primary antibody version, skip this step

• Final Preparation:

  • Wash cells and resuspend in appropriate buffer

  • Add viability dye if needed

  • Filter samples through 40-70 μm mesh to remove aggregates

• Analysis:

  • Analyze using flow cytometer with appropriate laser/filter settings

  • Use flow cytometry software (e.g., FlowJo) for data analysis

  • Expect positive signals primarily on the cell surface for IGF1R detection

For quantitative comparison, calculate mean fluorescence intensity and compare with appropriate controls to determine specific binding.

How does IGF1R signaling influence experimental outcomes?

IGF1R signaling can significantly impact experimental outcomes through multiple mechanisms that researchers must consider:

• Downstream Pathway Activation: IGF1R activation triggers several signaling cascades:

  • PI3K/AKT pathway: Promotes cell survival and metabolism

  • MAPK/ERK pathway: Drives cell proliferation and differentiation

  • JAK/STAT pathway: Regulates gene expression

• Cross-talk with Other Signaling Systems:

  • IGF1R can heterodimerize with insulin receptor (IR)

  • It interacts with other growth factor receptors (e.g., EGFR)

  • Estrogen receptor signaling can modulate IGF1R activity

• Experimental Considerations:

  • Serum starvation may be necessary to minimize baseline IGF1R activation

  • The phosphorylation status of IGF1R affects antibody binding in some epitopes

  • Cell confluence levels can affect receptor expression and activation

  • Cell type-specific differences in IGF1R expression levels must be accounted for

• Temporal Aspects:

  • Acute vs. chronic IGF1R stimulation produces different cellular responses

  • Receptor internalization and recycling dynamics affect signaling duration

When designing experiments involving IGF1R (Ab-1165/1166) Antibody, these signaling considerations should inform your experimental design, controls, and interpretation of results.

What are the key considerations for using IGF1R (Ab-1165/1166) Antibody in cancer research?

When utilizing IGF1R (Ab-1165/1166) Antibody in cancer research, researchers should address these critical considerations:

• Expression Heterogeneity:

  • IGF1R expression varies widely across cancer types and even within tumors

  • Confirm expression in your model system before extensive experimentation

  • Some cancer cell lines (e.g., DU-145) are IGF1R-positive while others (e.g., LNCaP) are IGF1R-negative

• Phosphorylation Status Analysis:

  • Total IGF1R vs. phosphorylated IGF1R provide different information

  • Consider using phospho-specific antibodies in parallel experiments

  • Activation status may not correlate with total protein levels

• Microenvironmental Factors:

  • Tumor microenvironment contains IGF1/IGF2 that may activate the receptor

  • Hypoxia can alter IGF1R expression and signaling

  • Stromal cells may contribute to IGF axis regulation

• Therapeutic Resistance Mechanisms:

  • IGF1R upregulation is associated with resistance to various targeted therapies

  • Compensatory signaling through insulin receptor may occur

  • Consider analyzing IR/IGF1R hybrid receptors

• In Vivo Models:

  • For xenograft studies, antibody specificity across species must be confirmed

  • Consider biodistribution studies to ensure tumor targeting

  • Control for endogenous mouse IGF1R vs. human tumor IGF1R

These considerations will enhance the rigor and reproducibility of cancer research involving IGF1R targeting and analysis.

How can IGF1R (Ab-1165/1166) Antibody be utilized for in vivo imaging studies?

For in vivo imaging applications, IGF1R (Ab-1165/1166) Antibody can be adapted using these methodological approaches:

• Antibody Modification for Imaging:

  • Conjugation with radioisotopes (e.g., 64Cu) for PET imaging

  • Fluorophore labeling for fluorescence imaging

  • Ensure conjugation preserves antibody binding properties

• Animal Model Selection:

  • Use xenograft models with confirmed IGF1R expression

  • Consider orthotopic models for physiologically relevant microenvironment

  • Include both IGF1R-positive (e.g., DU-145) and IGF1R-negative (e.g., LNCaP) tumors as controls

• Protocol Optimization:

  • Determine optimal antibody dose (typically 5-10 μg for mice)

  • Establish time course for optimal tumor-to-background ratio

  • Consider pharmacokinetic studies to determine ideal imaging time points

• Validation Approaches:

  • Perform ex vivo biodistribution studies to confirm imaging results

  • Correlate imaging signal with immunohistochemistry of harvested tissues

  • Use blocking studies with unlabeled antibody to confirm specificity

• Data Analysis:

  • Quantify signal using region-of-interest analysis

  • Calculate tumor-to-muscle or tumor-to-blood ratios

  • Analyze results using appropriate statistical methods (e.g., t-test with P<0.05 as significant)

This approach has been successfully employed for developing immunoPET tracers for prostate cancer imaging, demonstrating the feasibility of using anti-IGF1R antibodies for in vivo visualization of receptor expression.

What are common challenges when working with IGF1R (Ab-1165/1166) Antibody and how can they be addressed?

Researchers commonly encounter several challenges when working with IGF1R (Ab-1165/1166) Antibody:

• Specificity Issues:

  • Challenge: Cross-reactivity with insulin receptor due to homology

  • Solution: Validate specificity using IGF1R knockout/knockdown cells or IGF1R-negative cell lines like LNCaP

• Sensitivity Limitations:

  • Challenge: Detecting low abundance IGF1R expression

  • Solution: Implement signal amplification methods such as tyramide signal amplification; concentrate protein samples; use high-sensitivity detection reagents

• Background Signal:

  • Challenge: High background in immunostaining or Western blotting

  • Solution: Optimize blocking (5% BSA rather than milk for phospho-detection); increase washing steps; titrate antibody concentration; use more stringent washing buffers

• Receptor Activation Status:

  • Challenge: Distinguishing between active and inactive receptor

  • Solution: Include controls with IGF1 stimulation; use phospho-specific antibodies in parallel experiments

• Reproducibility Issues:

  • Challenge: Batch-to-batch variation in polyclonal antibodies

  • Solution: Purchase sufficient antibody for complete study; normalize to internal controls; consider monoclonal alternatives for critical applications

Addressing these challenges through methodological optimization will significantly improve experimental outcomes with this antibody.

How can researchers validate the specificity of IGF1R (Ab-1165/1166) Antibody in their experimental system?

To rigorously validate IGF1R (Ab-1165/1166) Antibody specificity in experimental systems, implement this comprehensive approach:

• Genetic Controls:

  • Use IGF1R knockdown/knockout models (siRNA, CRISPR-Cas9)

  • Compare IGF1R-positive (e.g., DU-145) vs. IGF1R-negative (e.g., LNCaP) cell lines

  • Express tagged versions of IGF1R for parallel detection

• Peptide Competition Assay:

  • Pre-incubate antibody with excess immunizing peptide (Ab-1165/1166 sequence)

  • Expected result: Signal elimination/reduction indicates specificity

• Multiple Detection Methods:

  • Compare results across different techniques (WB, flow cytometry, IHC)

  • Consistent detection pattern supports specificity

  • Use different antibodies targeting distinct IGF1R epitopes

• Functional Validation:

  • Correlate antibody signal with functional readouts of IGF1R activity

  • Stimulate cells with IGF1 and monitor receptor phosphorylation

  • Inhibit IGF1R with small molecule inhibitors and observe signal changes

• Molecular Weight Verification:

  • Confirm detection at expected molecular weights:

    • Full receptor: ~200 kDa

    • β-subunit: ~95 kDa

  • Verify changes in molecular weight following deglycosylation

These validation steps should be documented thoroughly and included in publications to support the reliability of research findings.

What are the critical parameters for optimizing IGF1R antibody conjugation for specialized applications?

For researchers pursuing specialized applications requiring IGF1R (Ab-1165/1166) Antibody conjugation, these critical parameters must be carefully optimized:

• Conjugation Chemistry Selection:

  • Consider the functional groups available on the antibody (lysines, cysteines)

  • Choose chemistry compatible with the label (fluorophore, enzyme, radioisotope)

  • Evaluate potential impact on antigen-binding region

• Antibody-to-Label Ratio Optimization:

  • Determine optimal degree of labeling (DOL)

  • Excessive labeling can impair binding affinity

  • Insufficient labeling reduces detection sensitivity

  • Typical optimal ranges:

    • Fluorophores: 2-6 molecules per antibody

    • Enzymes: 1-2 molecules per antibody

• Purification Considerations:

  • Remove unconjugated label thoroughly

  • Verify conjugate purity by spectroscopic methods

  • Consider size exclusion chromatography for optimal separation

• Stability Assessment:

  • Test storage conditions (temperature, buffer composition)

  • Determine shelf-life through time-course experiments

  • Add stabilizers if necessary (e.g., BSA, glycerol)

• Functional Validation:

  • Compare conjugated vs. unconjugated antibody performance

  • Test in all intended applications before large-scale use

  • Include appropriate controls for label-specific effects

Available conjugation options for IGF1R antibodies include:

• Fluorophores: AF350, AF488, AF555, AF594, AF647, and others

• Enzymes: HRP, Alkaline Phosphatase

• Tandem dyes: APC, PE combinations

• Small molecules: Biotin

• Traditional dyes: FITC, TRITC, Cy3, Cy5

How is IGF1R (Ab-1165/1166) Antibody being utilized in neurodegenerative disease research?

IGF1R (Ab-1165/1166) Antibody is finding important applications in neurodegenerative disease research, particularly in these emerging areas:

• Axonal Transport Studies:

  • IGF1R has been identified as a modulator of signaling endosome trafficking

  • Deficits in axonal transport are linked to various neurodegenerative conditions

  • The antibody enables visualization and tracking of IGF1R-containing endosomes

  • Research applications include studying the role of IGF1R in models of Amyotrophic Lateral Sclerosis (ALS)

• Neuroprotective Mechanisms:

  • IGF1R signaling promotes neuronal survival and axonal growth

  • The antibody allows correlation of receptor levels with neuroprotective outcomes

  • Enables investigation of IGF1R's role in preventing neuronal death

• Methodological Approaches:

  • Live-cell imaging of fluorescently labeled IGF1R antibodies

  • Co-localization studies with markers of retrograde and anterograde transport

  • Analysis of signaling endosome dynamics in neuronal cultures and brain slices

• Therapeutic Target Evaluation:

  • Assessment of IGF1R modulation as potential intervention strategy

  • Evaluation of compounds affecting IGF1R signaling in neurodegeneration models

  • Correlation of receptor expression with disease progression

This emerging research field connects IGF1R signaling with fundamental processes in neuronal maintenance and highlights the potential therapeutic implications of targeting this receptor in neurodegenerative conditions.

What are the latest developments in using IGF1R antibodies for therapeutic targeting research?

Recent advances in therapeutic targeting research utilizing IGF1R antibodies include:

• Dual-Targeting Approaches:

  • Development of bispecific antibodies targeting both IGF1R and other cancer-related receptors

  • Combined targeting of IGF1R and insulin receptor to prevent compensatory signaling

  • Evaluation of synergistic effects with standard chemotherapeutic agents

• Antibody-Drug Conjugates (ADCs):

  • Engineering IGF1R antibodies as delivery vehicles for cytotoxic payloads

  • Optimization of linker chemistry and drug-to-antibody ratios

  • Evaluation of tumor-selective delivery based on differential IGF1R expression

• Immune System Engagement:

  • Development of IGF1R antibodies that recruit immune effector cells

  • Investigation of antibody-dependent cellular cytotoxicity (ADCC) mechanisms

  • Combination strategies with immune checkpoint inhibitors

• Predictive Biomarkers:

  • Correlation of IGF1R expression levels with therapeutic response

  • Identification of molecular signatures predictive of response to IGF1R targeting

  • Development of companion diagnostics using IGF1R antibodies

• Novel Delivery Systems:

  • Nanoparticle formulations incorporating IGF1R antibodies for targeted delivery

  • Blood-brain barrier penetration strategies for CNS applications

  • Stimuli-responsive systems for conditional release at target sites

These developments represent cutting-edge applications of IGF1R antibodies beyond traditional research uses, highlighting their potential in translational medicine and therapeutic development.